Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Key findings from published and presented studies include: In a phase 2 obesity trial, higherdose retatrutide produced average weight loss of around 22.824.2% over 48 weeks in people with obesity. In participants with type 2 diabetes, retatrutide achieved substantial weight loss and marked improvements in blood sugar and cardiometabolic markers, though average percentage weight loss was somewhat lower than in nondiabetic obesity cohorts. Early studies also reported significant reductions in liver fat and visceral adipose tissue, with a high proportion of participants with fatty liver disease showing resolution of hepatic steatosis at higher doses. These results have led several reviews to describe retatrutide as a potential game changer in obesity pharmacotherapy, representing the first GLP1/GIP/glucagon triple agonist with robust human data. Popular coverage has highlighted phase 3 data suggesting average weight losses approaching 29% of body weight in some cohorts (roughly 71 pounds), which is about double typical results with semaglutide over comparable periods
A value above that range is called hypercobalaminemia
If you have insurance coverage for Zepbound, you can pay as low as $25 for a 1, 2, or 3-month supply
It works by moving fatty acids inside the cell, where they are converted to energy
Many users report increased energy and slight weight changes within the first few weeks
Because it's a new drug, its long-term safety has not been well studied
US$ 21.36
US$ 23.72
US$ 20.63
